Lower barthel index scores predict less prescription of pharmacological therapy in elderly patients with alzheimer disease

Dementia and Geriatric Cognitive Disorders

Volumn 29, Issue 3, 2010, Pages 198-203

  Formiga, Francesc ^a   Fort, Isabel ^b   Robles, Maria Jose ^c   Rodriguez, Daniel ^d   Regalado, Pedro ^e  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Alzheimer's Disease and Other Dementias Integral Care Unit   (Spain)

^c HOSPITAL DE L ESPERANÇA   (Spain)

^d Brain   (Spain)

^e Benito Menni Complex Assistencial en Salut Mental   (Spain)

Author keywords

Alzheimer disease; Dementia treatment; Elderly population study

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BARTHEL INDEX; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GERIATRIC ASSESSMENT; GLOBAL DETERIORATION SCALE; HUMAN; LAWTON INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 77949557068     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000278348     Document Type: Article

References (31)

1. Formiga F, Fort I, Robles MJ, Riu S, Sabartes O, Barranco E, Catena J: Comorbidity and clinical features in elderly patients with dementia: Differences according to dementia severity. J Nutr Health Aging 2009; 13: 423-427.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, rev. Washington, American Psychiatric Association, 2000.
3. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1:CD005593. (Pubitemid 46841366)
4. Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, Alpérovitch A: Memantine therapy for Alzheimer disease in real-world practice: An observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord 2008; 22: 125-130.
5. Whitehouse PJ, Price DL, Clark AW, Coyle JT, De Long MR: Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-126.
6. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, Memantine Study Group: Memantine in moderate-to-severe Alzheimer disease. N Engl J Med 2003; 348: 1333-1341.
7. McShane R, Areosa Sastre A, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006; 2:CD003154.
8. Tariot PN, Farlow MR, Grossberg GT Graham SM, McDonald S, Gergel I, Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004; 291: 317-324. (Pubitemid 38101604)
9. Emre M, Mecocci P, Stender K: Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer disease. J Alzheimers Dis 2008; 14: 193-199. (Pubitemid 352040033)
10. Sun Y, Lai MS, Lu CJ, Chen RC: How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: A national population-based study. Eur J Neurol 2008; 15: 278-283. (Pubitemid 351257924)
11. Jacobson SA, Sabbagh MN: Donepezil: potential neuroprotective and disease-modifying effects. Expert Opin Drug Metab Toxicol 2008; 4: 1363-1369.
12. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L: Diagnosis and treatment of dementia. 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 2008; 179: 1019-1026. (Pubitemid 351678349)
13. Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-1031.
14. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J: A 52-week study of the efficacy of rivastigmine in patients with mild-to-moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-241.
15. Doraiswamy PM, Krishnan KR, Anand R, Sohn H, Danyluk J, Hartman RD, Veach J: Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 705-712. (Pubitemid 34615976)
16. Formiga F, Fort I, Reig L, Robles MJ, Espinosa MC, Rodriguez D: Atrial fibrillation in elderly patients with dementia. Gerontology 2009; 55: 202-204.
17. Reisberg B, Ferris SH, De Leon MJ, Crok T: The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139. (Pubitemid 12051593)
18. McKhann C, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
19. Mahoney FI, Barthel DW: Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61-65.
20. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
21. Folstein MF, Folstein SE, McHugh PR: Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
23. Herrmann N, Binder C, Dalziel W, Smyth S, Camacho F: Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging 2009; 26: 403-407.
24. Doody R, Geldmacher D, Gordon B, Perdomo CA, Pratt R, Donepezil Study Group: Open-label, multicenter, phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001; 58: 427-433. (Pubitemid 32217459)
25. Zhu CW, Sano M: Economic considerations in the management of Alzheimer's disease. Clin Interv Aging 2006; 1: 143-154.
26. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, Rochon PA: Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population- based cohort study. Arch Intern Med 2009; 169: 867-873.
27. McLaren AT, Allen J, Murray A, Ballard CG, Kenny RA: Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15: 183-188. (Pubitemid 36302375)
28. Hernandez RK, Farwell W, Cantor MD, Lawler EV: Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. J Am Geriatr Soc 2009;DOI: 10.1111/j.1532-5415. 2009.02552.
29. Nordberg A, Svensson AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998; 19: 465-480. (Pubitemid 29015406)
30. Inglis F: The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002; 127: 45-63. (Pubitemid 34778530)
31. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003; 51: 937-944. (Pubitemid 36871141)